What the New Psychedelic Executive Order Actually Does — and What It Doesn’t

On April 18, 2026, the federal government issued an executive order titled Accelerating Medical Treatments for Serious Mental Illness — and our inbox lit up immediately. Customers, researchers, and fellow mycology enthusiasts wanted to know what it meant. We’ve been following psychedelic policy closely for years, and we want to give you our honest read: what this order actually does, what it doesn’t do, and what it means for the future of this medicine — and this community.

Let’s start with what we genuinely appreciate about this moment. Any federal action that treats psilocybin as medicine rather than a moral failing is progress. For decades, this substance has been stigmatized and scheduled in a way that made serious research nearly impossible. This order changes the conversation at the federal level, and that matters. It removes some of the stigma. It signals that the cultural tide has turned — that psilocybin and ibogaine deserve to be studied, not suppressed.

But we also want to be straight with you about what this order is not — and raise some questions that aren’t getting enough attention.

What the Executive Order Actually Does

The order directs the FDA, DEA, and HHS to accelerate research, review, and patient access for psychedelic compounds including psilocybin, ibogaine, MDMA, LSD, and methylone. It is a directive to federal agencies — not a law passed by Congress. It does not change the legal status of any psychedelic substance. But here’s what it actually does set in motion:

1. FDA Priority Review. The FDA is directed to issue Commissioner’s National Priority Vouchers for psychedelic drugs that already hold Breakthrough Therapy designation, compressing the standard review timeline from 10–12 months to as little as one to two months. Within days of signing, three vouchers were issued: two for psilocybin (treatment-resistant depression and major depressive disorder) and one for methylone, an MDMA analog studied for PTSD.

2. $50 million in federal-state matching funds. HHS, through ARPA-H, will allocate at least $50 million to support state governments developing psychedelic therapy programs. Oregon, Colorado, and Texas are the most obvious beneficiaries — though the matching structure will shape who actually captures those funds.

3. Right to Try access. The FDA and DEA are directed to establish a pathway for eligible patients with serious, treatment-resistant conditions to access investigational psychedelic compounds — including ibogaine — while still under FDA review. This is meaningful for patients who have run out of conventional options. It also comes with real risks (more on that below).

4. A rescheduling pathway. The Attorney General is directed to begin a DEA rescheduling review for any psychedelic that completes Phase 3 trials and earns FDA approval. Put simply — this order can’t reschedule anything on its own. It can only tell agencies to start the process the law already requires.

What the Order Does Not Do

This is the part that matters most for our community — and the part getting the least coverage.

For everyday mushroom enthusiasts, citizen scientists, and mycology hobbyists, the practical landscape hasn’t changed — at least not yet. Psilocybin mushrooms remain federally controlled substances under the Controlled Substances Act, exactly as they were before April 18th. Home cultivation and personal possession are still governed by the same federal and state laws that existed the day before the order was signed.

The legal landscape for mushroom spores and mycology supplies hasn’t changed either — our customers already know how to navigate what’s permitted in their state, and that remains true. For spore companies like PNW Spore, our operation hasn’t changed. Our products are sold for microscopy, taxonomy, and education, and that remains true regardless of where federal psychedelic policy goes.

Curious about the microscopy side of mycology? Our spore syringes and spore prints are used by students, independent researchers, and educators to study these organisms up close — exactly the kind of foundational science this policy moment makes more important than ever.

Who Was in the Room

The order was signed at the White House with a small group that included podcaster Joe Rogan, ibogaine advocate W. Bryan Hubbard, former Navy SEAL Marcus Luttrell and his brother U.S. Representative Morgan Luttrell of Texas, HHS Secretary Robert F. Kennedy Jr., and FDA Commissioner Dr. Martin Makary.

We’ll say what others aren’t: the effort to bring psychedelic medicines into mainstream science predates this administration by decades — and the human relationship with these fungi predates modern science by centuries. The story of psilocybin mushrooms runs through indigenous ceremonial traditions, through the spiritual significance of fungi across cultures and across time. It belongs to generations of researchers, clinicians, indigenous knowledge-holders, advocacy nonprofits, and the voters in states and cities who pushed this forward. This order accelerates one piece of that much longer story. It did not create it. The people — and the traditions — that built this movement deserve that acknowledgment.

The Questions We’re Actually Asking

We support psychedelic research. We believe psilocybin has genuine therapeutic potential and that the Schedule I classification has caused serious harm — to patients who needed treatment, to researchers who couldn’t do their work, and to public understanding of fungi as medicine. But support for the science doesn’t require silence about the trade-offs in this particular policy path.

The pharmaceutical control question

This is the one we keep coming back to. Psilocybin is a compound produced by fungi that humans have studied and cataloged for decades. Yet a small number of pharmaceutical companies have already secured U.S. patents covering specific synthetic forms, manufacturing methods, and therapeutic protocols built around psilocybin. Reporting in the American Prospect and analysis in the Harvard Law Review have raised concerns that these patent strategies could allow a handful of companies to set the terms of the market and the price of treatment.

We want to be direct: there is a real risk that this executive order accelerates a model in which access to psilocybin is controlled entirely by pharmaceutical companies and available only through expensive clinical settings — while the fungus itself, the spore, the living organism, remains illegal for ordinary people to grow, study, or understand. That’s not a conspiracy theory. That’s a foreseeable outcome of the FDA-and-pharma-only pathway, and it deserves to be named.

“A future in which psilocybin is available by prescription from a licensed clinic but illegal to study, grow, or identify in any other context is not a future we would call progress. It’s a future in which a medicine that has been part of human culture for thousands of years becomes a product owned by a handful of companies.”

— Bonnie, PNW Spore

The cost question

In Oregon and Colorado, where supervised psilocybin therapy is already legal, a single dosing session runs $1,000 to $3,500, and a full course of treatment can reach $8,000 or more. Insurance rarely covers it. An FDA-approved pharmaceutical version could be cheaper at scale — or it could follow the pricing patterns of other patented breakthrough therapies. That is an open empirical question. We don’t know the answer. Neither does anyone else.

The pace question

Mason Marks, a leading legal scholar on psychedelic policy at Harvard Law School, has cautioned that approving treatments under political pressure that shouldn’t yet be approved “wouldn’t be good for anyone” and could set the entire field back if a high-profile failure followed. Ibogaine in particular has known cardiac risks; NIH-funded research on it was halted in the 1990s over cardiotoxicity concerns, and reasonable scientists still disagree about whether it currently meets the basic safety threshold the federal Right to Try Act assumes.

Where State Programs Stand

Oregon and Colorado have legalized supervised, regulated psilocybin therapy. New Mexico has been moving in the same direction. The executive order does not preempt these programs — it positions the federal government to fund and learn from them.

Texas established a $100 million ibogaine research initiative in 2025 — $50 million in state funding matched by private partners — making it the largest publicly funded psychedelic research investment in U.S. history. Texas is widely expected to be a major beneficiary of the new federal-state matching funds. More than two dozen U.S. cities and a handful of additional jurisdictions have passed their own measures of varying scope. Here’s a quick snapshot of where things stand as of this writing:

One Month In: What’s Actually Happened

The most significant follow-through came from a direction most people weren’t watching. On April 23 — five days after the psychedelics signing — Acting Attorney General Todd Blanche issued a separate DOJ order immediately moving FDA-approved marijuana products and state-licensed medical marijuana from Schedule I to Schedule III. A formal rescheduling hearing for broader marijuana reclassification is now set for June 29, 2026. Read together, the two actions suggest the administration is moving on multiple controlled-substance fronts simultaneously, not just psychedelics in isolation.

On the research infrastructure side, the DEA finalized its 2026 aggregate production quotas with notable increases: psilocybin up to 50,000 grams (from 30,000 in 2025), psilocin more than doubled to 80,000 grams, and DMT raised to 25,000 grams. These aren’t consumer supply figures — they’re research-only ceilings — but they signal that the pipeline is being actively built out.

What hasn’t moved: the DEA rescheduling review for psilocybin specifically. Despite commitments from the DEA administrator, that process remains stalled as of late May. This is consistent with what legal scholars said at signing — executive orders can direct agencies to act, but they can’t compel the pace.

And not everyone in the scientific community is cheering. In a May 6 piece in STAT News, Peter S. Hendricks, Ph.D. — a university professor of psychiatry and behavioral neurobiology — voiced support for the order’s goals while questioning whether the field is moving too fast. His concern — one we share — is that ibogaine is receiving outsized political attention due to the veteran advocacy coalition and media momentum, while psilocybin and MDMA have far more mature safety and efficacy data and are better positioned for responsible near-term approval. Moving fast on the less-studied compound first is a risk the whole field would absorb if something went wrong.

What This Means for Mycology — and Why We’re Paying Attention

We’re glad psilocybin is finally being taken seriously as medicine. It deserves that — and it’s taken far too long. But we are genuinely concerned about what gets lost if the only pathway that survives is a pharmaceutical one.

Fungi are not pharmaceuticals. They are living organisms with genetic diversity that has developed over millions of years. The strains we study, catalog, and preserve at PNW Spore represent a fraction of that diversity — but they represent something that cannot be recreated in a lab once it’s gone. The cultural and scientific knowledge around psilocybin mushrooms — how to identify them, how to preserve them, how to understand them as part of a broader ecosystem — is knowledge that belongs to the commons. It has been built by indigenous communities, amateur naturalists, citizen scientists, and researchers over generations.

Our concern is this: as pharmaceutical companies make large bets on synthetic psilocybin and proprietary protocols, the pressure to restrict access to the living organism — the fungus, the spore — will increase, not decrease. A future in which psilocybin is available by prescription but illegal to study, grow, or identify in any other context is not progress. It’s a future in which a medicine that has been part of human culture for thousands of years becomes a product owned by a handful of companies.

That’s the part of this executive order that isn’t in the headlines. And it’s the part we think our community needs to be thinking about.

Where PNW Spore Fits In

What we believe in is the value of preservation, identification, and education. Fungi are one of the most consequential and least-understood kingdoms of life. The genetic diversity that underwrites everything from soil health to medicine to mental-health research lives in spore libraries, herbaria, and the careful work of amateur and professional mycologists. Making that genetic diversity available to students, researchers, and curious citizens is, in our view, foundational science work.

This executive order makes that work more important, not less. A future in which psilocybin-containing fungi are the subject of national policy and pharmaceutical investment is a future in which mycology literacy matters more than ever. Someone needs to preserve the genetic diversity. Someone needs to do the taxonomy. Someone needs to make sure the public understanding of these organisms isn’t entirely shaped by drug companies with a financial interest in one synthetic compound.

That’s the work we intend to keep doing — carefully, legally, and with the same commitment to accuracy and transparency that has guided this company since we opened.

Preserving genetic diversity starts with having access to it. Our catalog includes over 60 cultivars from around the world — available for microscopy and taxonomic study.

— PNW Spore

PNW Spore is a mycology supplier. Our spores are sold strictly for microscopy, taxonomy, and education. Nothing in this article is a recommendation, encouragement, or endorsement of any unlawful activity. The legality of our products varies by state – please familiarize yourself with the laws in your area before purchasing.

Sources

1. The White House, “Accelerating Medical Treatments for Serious Mental Illness” (Presidential Action, April 18, 2026).
2. CNN, “FDA moves to fast-track review of psilocybin and methylone for mental health” (April 24, 2026).
3. The White House, “Fact Sheet: Accelerating Medical Treatments for Serious Mental Illness” (April 2026).
4. TIME, “What to Know About Trump’s New Executive Order on Psychedelic Drugs” (April 21, 2026).
5. Petrie-Flom Center, Harvard Law School, “A New Executive Order on Psychedelics: Q&A with I. Glenn Cohen and Mason Marks” (April 18, 2026).
6. TIME, “What to Know About Trump’s New Executive Order on Psychedelic Drugs” (April 21, 2026).
7. NPR, “Trump signs order fast tracking review of psychedelics for mental health disorders” (April 18, 2026).
8. Wikipedia, “Psilocybin decriminalization in the United States.”
9. The American Prospect, “Rollups: The Emerging Magic Mushroom Monopoly” (January 10, 2022).
10. Harvard Law Review, “Patents on Psychedelics: The Next Legal Battlefront of Drug Development” (2022).
11. 9News (Denver), “Psilocybin therapy in Colorado could cost thousands, won’t be covered by insurance.”
12. Willamette Week, “Bend Psilocybin Center Becomes First in Oregon to Offer Insurance Coverage” (April 19, 2025).
13. Petrie-Flom Center, Harvard Law School, “A New Executive Order on Psychedelics” (April 18, 2026).
14. Scientific American, “Trump’s order on psychedelics could have far-reaching science consequences.”
15. TIME, “What to Know About Trump’s New Executive Order on Psychedelic Drugs” (April 21, 2026).
16. Texas ibogaine research consortium reporting, 2025.
17. Wikipedia, “Psilocybin decriminalization in the United States.”
18. U.S. Department of Justice, “Justice Department Places FDA-Approved Marijuana Products… in Schedule III” (April 23, 2026).
19. Marijuana Moment, “DEA Boosts Legal Production Levels For Psychedelics Like Psilocybin And DMT In Final Rule For 2026.”
20. Reason.org Psychedelics Policy Newsletter, “DEA considers rescheduling psilocybin, FDA releases rejection decision, and more.”
21. STAT News, “Trump’s executive order on psychedelics is the right move. But is my field ready for it?” (May 6, 2026).